中國抗體(03681.HK)獲香港科學園800萬元專項補貼
中國抗體(03681.HK)公佈,近日獲得香港科技園公司(香港科學園)臨牀轉化促成(CTC)計劃中800萬港元專項補貼,該補貼庶計劃最高補貼金額。
根據雙方簽訂的協議,香港科學園將在未來42個月內向中國抗體按照臨牀計劃及進展分階段提供上述補貼,用於公司主要產品SN1011針對多發性硬化(MS)症的臨牀試驗。公司未來將充分把握機遇,加快推進各項產品的研發工作和臨牀試驗,同時進一步擴大產品管線及潛在適應症,加快實現產品商業化目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.